Biotechnology

Wednesday Aug 07, 2024 - 9:54 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), today released its Q2 2024 financial results. In addition, the company provided recent updates on its CNM-Au8(R) programs evaluating the use of CNM-Au8…

Wednesday Aug 07, 2024 - 9:42 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of…

Tuesday Aug 06, 2024 - 12:33 pm

InvestorNewsBreaks — Astiva Health Announces Launch of Investor Relations Website to Facilitate Transparent, Effective Communication

Astiva Health, a leader in innovative and culturally aware healthcare solutions, today announced the launch of its new Investor Relations website. The launch marks a significant step and milestone in the company’s journey towards becoming a public company. It emphasizes Astiva Health’s commitment to maintaining transparent and effective communication and building strong relationships with investors, stakeholders, and the broader financial community. The platform will offer…

Tuesday Aug 06, 2024 - 11:22 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA

Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary Clene Nanomedicine Inc., have submitted new data to the U.S. Food and Drug Administration (“FDA”). The data is regarding CNM-Au8(R) biomarker and clinical efficacy information, including post hoc analyses from two phase 2 clinical trials of CNM-Au8 for the treatment of ALS; the…

Tuesday Aug 06, 2024 - 9:37 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is planning to release its second-quarter 2024 financial report after markets close on Aug. 14, 2024. The company also announced that it has scheduled a conference call and webcast on the same day to discuss the report and provide a company update; the call will begin at…

Monday Aug 05, 2024 - 3:08 pm

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Preparing for NDA Submission for Leading Drug Candidate

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the process of preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”). The NDA is for PAX-101, an intravenous formulation of suramin that could potentially treat conditions such as Human African Trypanosomiasis and autism spectrum disorder (“ASD”). The process includes having a Type…

Monday Aug 05, 2024 - 10:56 am

InvestorNewsBreaks – TRxADE Health Inc.’s (NASDAQ: MEDS) Subsidiary Expands Capabilities with Changes to Executive Leadership Team

TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, and its wholly owned subsidiary Scienture, LLC, a New York based branded specialty pharmaceutical company, today announced changes to Scienture’s executive leadership team. According to the announcement, Narasimhan Mani, Ph.D., MBA, an experienced healthcare professional and a proven health leader with over 25 years of experience in the pharmaceutical industry, has been appointed Scienture’s President. Additionally,…

Monday Aug 05, 2024 - 9:40 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Featured in Latest Bell2Bell Podcast, Recorded Live at AAIC 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is spotlighted in the latest episode of The Bell2Bell Podcast, released by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. The episode, which featured Annovis Bio founder, president and CEO Dr. Maria Maccecchini, PhD, was recorded…

Monday Aug 05, 2024 - 9:28 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation in Upcoming Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is set to present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase and host 1x1 investor…

Friday Aug 02, 2024 - 10:40 am

InvestorNewsBreaks — Better Choice Company (NYSE American: BTTR) Closes on $5M Public Offering

Better Choice Company (NYSE American: BTTR), a pet health and wellness company, has closed on its public offering. The offering consisted of 639,000 shares of common stock as well as prefunded warrants to purchase 1,028,000 shares of its common stock. According to the announcement, each share of common stock and prefunded warrant was sold at $3 per share (inclusive of the prefunded warrant exercise price),…

Friday Aug 02, 2024 - 9:47 am

InvestorNewsBreaks – CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering

CEL-SCI (NYSE American: CVM), a cancer immunotherapy company, recently announced the closing of its previously announced best-efforts offering. The transaction involved the sale of 10,845,000 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per unit (inclusive of the pre-funded warrant exercise price). The offering raised $10,845,000 in gross proceeds before deductions. CEL-SCI intends to use…

Monday Jul 29, 2024 - 9:09 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Lomecel-B(TM) Study Results Presented at the Alzheimer’s Association International Conference

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is presenting results from its Clear Mind phase 2a clinical trial at the Alzheimer’s Association International Conference(R) (“AAIC”). The conference began on July 28, 2024, and runs through Aug. 1, 2024; the event is being held in person in Philadelphia as well as online. According to the announcement,…

Friday Jul 26, 2024 - 12:47 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is scheduled for Sept. 9–11, 2024, and will be held both virtually and in person in New York City. According to the announcement, virtual participation will be staged simultaneously with…

Friday Jul 26, 2024 - 11:57 am

InvestorNewsBreaks – TRxAde Health Inc. (NASDAQ: MEDS), Scienture Inc. Announce All-Stock Business Combination Resulting in Combined Company

TRxADE Health (NASDAQ: MEDS), a parent company of pharmaceutical business-to-business (“B2B”) exchange platform, has entered into a business combination with Scienture Inc. in an all-stock transaction. Scienture is a New-York-based pharmaceutical company that develops unique specialty product concepts and solutions. According to the announcement, TRxADE acquired all of Scienture’s assets in exchange for a combination of TRxADE common stock and nonvoting convertible preferred stock. In addition,…

Thursday Jul 25, 2024 - 12:42 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CMO to Present Poster at Upcoming SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held Aug. 8–10 in Denver. According to the announcement, CNS Pharmaceuticals has an abstract, titled “Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases:…

Thursday Jul 25, 2024 - 12:31 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its wholly owned subsidiary, Adivir Inc., have signed a second Amending Agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) regarding its previously announced acquisition agreement. A biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures, Appili has raised C$100 million toward developing its therapeutics since its inception…

Wednesday Jul 24, 2024 - 9:24 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Holds Annual General and Special Meeting of Shareholders, Reports on Voting Results

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is reporting on the results of its annual general and special meeting of shareholders; the in-person meeting was held on July 22, 2024, in Toronto, Ontario. According to the report, shareholders were represented in person or by proxy at the meeting. Shareholders elected…

Tuesday Jul 23, 2024 - 11:43 am

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Inks Middle East License, Supply Agreement for Proprietary Birth Control Product

Evofem Biosciences Inc. (OTCQB: EVFM), a company commercializing innovative products to address unmet needs in women's sexual and reproductive health, has signed a license and supply agreement for the Middle East rights to Phexxi(R), Evofem's FDA-approved, hormone-free contraceptive, with private Emirati health care company Pharma 1 Drug Store LLC. Evofem and Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with…

Tuesday Jul 23, 2024 - 10:05 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received the minutes of meeting from a recent Scientific Advice (“SA”) with the Paul Erlich Institute, Federal Institute for Vaccines and Biomedicines (“PEI”). According to the announcement, this is the European equivalent to…

Monday Jul 22, 2024 - 9:53 am

InvestorNewsBreaks — Onassis Holdings Corp. (ONSS) Enters Agreement with Dalmore Group for Reg A+ Offering

Onassis Holdings (OTC: ONSS), a wellness- and biotech-focused holding company, has launched a round of Regulation A+ financing. The company has entered an agreement with Dalmore Group for the fundraising initiative. According to the announcement, Reg A+ funding offers a streamlined method for companies to raise up to $75 million a year from the public. “In aligning with Dalmore Group, Onassis looks to leverage the investment bank's…

Monday Jul 22, 2024 - 9:19 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on $9M Registered Direct Offering

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market following NASDAQ rules, included the issue and sale of 2,236,026 shares of LGVN Class A common stock (or common stock equivalents in lieu thereof). The shares were offered at a purchase price…

Friday Jul 19, 2024 - 11:31 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per unit in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Silo Pharma…

Friday Jul 19, 2024 - 10:02 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Execs to Participate in July 25 Investor Webinar

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and President Serguei Melnik and CEO Gareth Sheridan will share insights into the company’s current operations and upcoming milestones. To register for…

Thursday Jul 18, 2024 - 10:01 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Device and CMC Development Master Plan to Support IND-Enabling Study of SPC-15

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into a Device and CMC Development Master Plan with medical technology provider Resyca BV. A joint venture between Bespak Group and Medspray Pharma BV, Resyca manufactures the formulation-specific microchip-based spray system that Silo has chosen for its lead candidate SPC-15, an…

Wednesday Jul 17, 2024 - 10:47 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Evofem Biosciences (EVFM) Announce Amended, Restates Merger Agreement

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, along with its wholly owned subsidiary Adifem Inc., and Evofem Biosciences Inc. (OTCQB: EVFM) have amended and restated their previously announced merger agreement. According to the announcement, the amended and restated agreement addresses several issues, including preclosing matters such as interim financing needs that are critical for Evofem’s future success and substituting cash…

Tuesday Jul 16, 2024 - 3:30 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names New Medical Advisory Board Member

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, has appointed a new member to its medical advisory board. According to the announcement, Mark Gilbert, MD, will be joining the board, bringing board membership to eight. A scientist emeritus at the National Institutes of Health (“NIH”), Gilbert served as chief of the neurooncology branch at NIH for a decade.…

Tuesday Jul 16, 2024 - 2:51 pm

InvestorNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Closes $8.75M Underwritten Public Offering

Bluejay (NASDAQ: BJDX), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, recently announced the closing of a firm commitment underwritten public offering. Expected gross proceeds to the company were approximately $8.75 million. The base offering consisted of 5,368,098 common units or prefunded units, each unit consisting of one share of the company’s common stock…

Tuesday Jul 16, 2024 - 2:31 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Exec to Present at Upcoming Virtual Investor Closing Bell Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be presenting via a live video webcast at 4 p.m. on July 17. The presentation will include a corporate…

Monday Jul 15, 2024 - 11:22 am

InvestorNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT), KeHE Join Forces to ‘Bring Safety Shot to the Masses’

Safety Shot (NASDAQ: SHOT) today announced its strategic partnership with KeHE Distributors, a leading natural and organic, specialty and fresh food distributor in North America. The collaboration expands Safety Shot’s presence to a broader audience and enhances consumer accessibility nationwide. Under the partnership, KeHE Distributors, renowned as one of the nation’s largest and most respected pure-play grocery and natural distributors, will play a pivotal role…

Friday Jul 12, 2024 - 1:15 pm

InvestorNewsBreaks – Astiva Health Providing Tailored Approach to Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, recognizes that successful treatment outcomes are largely dependent on the patient, with 90% of treatment success attributed to patient involvement. Patient engagement can lead to reduced hospitalizations as well as improve effectiveness, efficiency, quality of health services, quality of life, and responsiveness. “Astiva Health is leading the…

Friday Jul 12, 2024 - 12:27 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management Slated to Participate in Upcoming Emerging Growth Conference

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will be participating in next week’s Emerging Growth Conference. According to the announcement, members of Clene’s management team will be presenting at the one-day conference, which is scheduled…

Thursday Jul 11, 2024 - 2:00 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment

InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Degeneration (“AMD”) and its INM-901 small molecule drug candidate targeting Alzheimer’s disease (“AD”). “Recent preclinical data for INM-089 demonstrated significant functional and pathological improvements in an…

Thursday Jul 11, 2024 - 1:05 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Prepares to Submit Briefing Book to FDA, Looks to Obtain Key Feedback Regarding NDA for CNM-Au8 in ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is in the process of submitting a briefing book to the U.S. Food and Drug Administration (“FDA”). The company anticipates submitting the book by July 13, 2024, in…

Wednesday Jul 10, 2024 - 12:30 pm

InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Sets New Standard for Accuracy, Reliability in Narcotics Detection

Astrotech (NASDAQ: ASTC), through its subsidiary 1st Detect, is revolutionizing narcotics and explosives trace detection. “With recent approval as a U.S. General Services Administration (‘GSA’) authorized vendor, 1st Detect is poised to expand its impact across government agencies. TRACER 1000 is a cutting-edge detector utilizing ruggedized mass spectrometry technology for superior detection at critical security points. 1st Detect’s commitment to excellence is underscored by its…

Tuesday Jul 09, 2024 - 2:26 pm

InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings

IGC Pharma (NYSE American: IGC) today announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer’s murine models indicates that TGR-63 has the potential to cross the blood-brain barrier in humans. The findings build on earlier results demonstrating TGR-63’s efficacy in reducing amyloid plaque in Alzheimer’s mouse models. “These…

Tuesday Jul 09, 2024 - 1:40 pm

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Elected New Board Member at Annual Stockholder Meeting

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (“HLHS”) and Alzheimer’s disease, is announcing an addition to its board of directors. According to the announcement, senior healthcare investment banker Neha Motwani was elected to the board during the company’s recent Annual Meeting of Stockholders. Motwani brings more than two decades of experience to…

Tuesday Jul 09, 2024 - 1:23 pm

InvestorNewsBreaks – VolitionRx Limited (NYSE American: VNRX) appoints PharmaVentures for Capture PCR(TM) and Oncology Portfolio Licensing

VolitionRx Limited (NYSE American: VNRX), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, announced the engagement of PharmaVentures Ltd (“PharmaVentures”) to act as an advisor. PharmaVentures will provide strategic advice and transactional support as Volition works towards securing licensing deals with industry leaders for both Nu.Q(R) Cancer – a range of simple blood-based assays to…

Tuesday Jul 09, 2024 - 10:44 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has announced that four new executives will be joining the company’s management team. The four new leaders include Mark White as chief business officer; Alexander Morris, PhD, as director of strategic communications; Hilda Maibach as senior vice president of statistics; and Blake…

Monday Jul 08, 2024 - 1:33 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees “Swell” of Insider Investments, Upgrade in Ranking after Positive Year-End Report

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases following the company’s year-end update; the report highlighted significant advancements that strengthened Cybin’s position in the development of next-generation psychedelic-based therapeutics. In the announcement, Cybin noted that “fast-moving sectors need equally…

Monday Jul 08, 2024 - 10:29 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced its receipt of an updated non-binding letter of intent (“LoI”) from the European Investment Bank (“EIB”). The updated LoI outlines specific terms for converting the majority of the EIB’s loan into equity in the form of…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions